Osimertinib for lung cancer after adjuvant targeted therapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a targeted therapy pill called osimertinib can work for people whose non-small cell lung cancer came back after they had surgery and completed a course of adjuvant EGFR TKI therapy (like gefitinib or erlotinib). If your cancer has an EGFR mutation and you meet the other health criteria, this trial may offer an additional treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had surgery for stage IB to IIIB non-small cell lung cancer, followed by adjuvant targeted therapy (an EGFR TKI pill) for at least 3 months, and your cancer came back more than 3 months after finishing that treatment.
- Your tumor has a specific EGFR gene mutation (like exon 19 deletion or L858R), as confirmed by a lab test.
- You are in fairly good health (able to take care of yourself and do daily activities) and are expected to live at least 12 weeks.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are not pregnant and agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This study tests whether osimertinib can prevent remaining abnormal lung spots (called ground-glass nodules) from growing after surgery. It is for people with lung cancer caused by specific EGFR gene changes (L858R or exon 19 deletion).
Hear when a new Lung Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.